Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 1
1990 1
1991 1
1992 2
1997 1
1998 1
2000 3
2002 5
2003 1
2004 3
2005 2
2006 2
2007 3
2008 9
2009 2
2010 1
2011 3
2012 10
2013 5
2014 5
2015 1
2016 3
2017 2
2018 3
2019 4
2020 2
2021 7
2022 9
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Results by year

Filters applied: . Clear all
Page 1
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens.
Podzamczer D, Imaz A, Lopez-Lirola A, Knobel H, Masiá M, Fanciulli C, Hernández C, Lagarde M, Gutierrez A, Curran A, Morano L, Montero-Alonso M, Troya J, Rigo R, Casadellà M, Navarro-Alcaraz A, Ardila F, Parera M, Bernal E, Echeverria P, Estrada V, Hidalgo-Tenorio C, Macias J, Prieto P, Portilla J, Valencia E, Vivancos MJ, Rivero A. Podzamczer D, et al. Among authors: parera m. J Antimicrob Chemother. 2023 Nov 6;78(11):2696-2701. doi: 10.1093/jac/dkad285. J Antimicrob Chemother. 2023. PMID: 37725999 Clinical Trial.
Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial.
Bailón L, Llano A, Cedeño S, Escribà T, Rosás-Umbert M, Parera M, Casadellà M, Lopez M, Pérez F, Oriol-Tordera B, Ruiz-Riol M, Coll J, Perez F, Rivero À, Leselbaum AR, McGowan I, Sengupta D, Wee EG, Hanke T, Paredes R, Alarcón-Soto Y, Clotet B, Noguera-Julian M, Brander C, Molto J, Mothe B; AELIX002 Study Group. Bailón L, et al. Among authors: parera m. Nat Med. 2022 Dec;28(12):2611-2621. doi: 10.1038/s41591-022-02060-2. Epub 2022 Oct 27. Nat Med. 2022. PMID: 36302893 Clinical Trial.
[Molecular aspects of duodenal iron absorption].
Guix P, Parera M, Castro JA, Picornell A, Ramón MM, Obrador A. Guix P, et al. Among authors: parera m. Gastroenterol Hepatol. 2003 Feb;26(2):86-93. doi: 10.1016/s0210-5705(03)79047-5. Gastroenterol Hepatol. 2003. PMID: 12570892 Review. Spanish. No abstract available.
Update on novel therapeutic agents for cervical cancer.
del Campo JM, Prat A, Gil-Moreno A, Pérez J, Parera M. del Campo JM, et al. Among authors: parera m. Gynecol Oncol. 2008 Sep;110(3 Suppl 2):S72-6. doi: 10.1016/j.ygyno.2008.04.016. Epub 2008 Jun 9. Gynecol Oncol. 2008. PMID: 18544460 Review.
Gut microbiome signatures linked to HIV-1 reservoir size and viremia control.
Borgognone A, Noguera-Julian M, Oriol B, Noël-Romas L, Ruiz-Riol M, Guillén Y, Parera M, Casadellà M, Duran C, Puertas MC, Català-Moll F, De Leon M, Knodel S, Birse K, Manzardo C, Miró JM, Clotet B, Martinez-Picado J, Moltó J, Mothe B, Burgener A, Brander C, Paredes R; BCN02 Study Group. Borgognone A, et al. Among authors: parera m. Microbiome. 2022 Apr 11;10(1):59. doi: 10.1186/s40168-022-01247-6. Microbiome. 2022. PMID: 35410461 Free PMC article. Clinical Trial.
Evolution of the gut microbiome following acute HIV-1 infection.
Rocafort M, Noguera-Julian M, Rivera J, Pastor L, Guillén Y, Langhorst J, Parera M, Mandomando I, Carrillo J, Urrea V, Rodríguez C, Casadellà M, Calle ML, Clotet B, Blanco J, Naniche D, Paredes R. Rocafort M, et al. Among authors: parera m. Microbiome. 2019 May 11;7(1):73. doi: 10.1186/s40168-019-0687-5. Microbiome. 2019. PMID: 31078141 Free PMC article.
Vaccination with an HIV T-cell immunogen induces alterations in the mouse gut microbiota.
Borgognone A, Elizalde-Torrent A, Casadellà M, Romero L, Escribà T, Parera M, Català-Moll F, Noguera-Julian M, Brander C, Olvera A, Paredes R. Borgognone A, et al. Among authors: parera m. NPJ Biofilms Microbiomes. 2022 Dec 30;8(1):104. doi: 10.1038/s41522-022-00368-y. NPJ Biofilms Microbiomes. 2022. PMID: 36585401 Free PMC article.
Probiotic effects on immunity and microbiome in HIV-1 discordant patients.
Blázquez-Bondia C, Parera M, Català-Moll F, Casadellà M, Elizalde-Torrent A, Aguiló M, Espadaler-Mazo J, Santos JR, Paredes R, Noguera-Julian M. Blázquez-Bondia C, et al. Among authors: parera m. Front Immunol. 2022 Dec 8;13:1066036. doi: 10.3389/fimmu.2022.1066036. eCollection 2022. Front Immunol. 2022. PMID: 36569851 Free PMC article. Clinical Trial.
86 results